Mulet-Margalef et al., 2023 - Google Patents
Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscapeMulet-Margalef et al., 2023
View HTML- Document ID
- 8454415081256376900
- Author
- Mulet-Margalef N
- Linares J
- Badia-Ramentol J
- Jimeno M
- Sanz Monte C
- Manzano Mozo J
- Calon A
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Between 5% and 15% of colorectal cancers (CRC) show deficiencies in the mismatch repair machinery and high microsatellite instability (dMMR/MSI-H). dMMR/MSI- H CRC is characterized by a dysfunctional DNA repair system, which renders the tumor …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Takei et al. | The new era of immunotherapy in gastric cancer | |
Mulet-Margalef et al. | Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape | |
Lichtenstern et al. | Immunotherapy, inflammation and colorectal cancer | |
Taieb et al. | Adjuvant chemotherapy for stage III colon cancer | |
Boyero et al. | Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy | |
Passardi et al. | Immune checkpoints as a target for colorectal cancer treatment | |
Cesano et al. | Bringing the next generation of immuno-oncology biomarkers to the clinic | |
Copija et al. | Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients | |
Wojas-Krawczyk et al. | Beyond PD-L1 markers for lung cancer immunotherapy | |
Pagni et al. | Targeting immune-related biological processes in solid tumors: we do need biomarkers | |
Singh et al. | The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy | |
Vallilas et al. | Gastrointestinal stromal tumors (GISTs): novel therapeutic strategies with immunotherapy and small molecules | |
Kim et al. | Current status and future perspectives of checkpoint inhibitor immunotherapy for prostate cancer: a comprehensive review | |
Tunger et al. | The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy | |
Zhang et al. | Precision immuno-oncology: prospects of individualized immunotherapy for pancreatic cancer | |
Otoshi et al. | Possible biomarkers for cancer immunotherapy | |
Huyghe et al. | Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine | |
Palicelli et al. | What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review (part 6): correlation of PD-L1 expression with the status of mismatch repair system, BRCA, PTEN, and other genes | |
Fugazzola et al. | Intratumoral genetic heterogeneity in papillary thyroid cancer: occurrence and clinical significance | |
Rebuzzi et al. | Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives | |
Ros et al. | Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers | |
Iivanainen et al. | Possibilities of improving the clinical value of immune checkpoint inhibitor therapies in cancer care by optimizing patient selection | |
Pinto et al. | Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives | |
Li et al. | Programmed death ligand 1 indicates pre-existing adaptive immune response by tumor-infiltrating CD8+ T cells in non-small cell lung cancer | |
Sesma et al. | From tumor mutational burden to blood T cell receptor: looking for the best predictive biomarker in lung cancer treated with immunotherapy |